The global pemphigus vulgaris market is experiencing steady growth, driven by the rising prevalence of autoimmune skin disorders, increasing awareness of rare diseases, and advancements in biologic and immunosuppressive therapies. The development of monoclonal antibodies and targeted therapies has significantly improved treatment options, offering better disease management and improved patient outcomes. Government initiatives, orphan drug designations, and research funding are further supporting market expansion. Continued innovation in biologics and expanding clinical research suggest a positive growth trajectory.
Global Pemphigus Vulgaris Market is valued at 9,819.75 million in 2022 and is expected to reach USD 677.32 million by 2030, with a growing CAGR of 8.2% during the forecast period 2023 to 2030.
To know more, visit https://www.databridgemarketresearch.com/reports/global-pemphigus-vulgaris-market
Below are the Top Pemphigus Vulgaris Companies with a Significant Market Share:
|
Rank
|
Company
|
Overview
|
Product Portfolio
|
Sales Geographical Coverage
|
Developments
|
|
1.
|
Abbvie Inc.
|
AbbVie has developed Rituxan (rituximab), a monoclonal antibody targeting CD20-positive B cells, which are implicated in the autoimmune response seen in PV. Rituxan has been approved for the treatment of moderate to severe pemphigus vulgaris and has become a cornerstone therapy in managing this condition.
|
|
North America, South America, Middle East and Africa, Asia-Pacific, and Europe
|
In June 2023, AbbVie Inc. announced that in patients with previously untreated CLL with co-existing diseases, as well as R/R CLL, VENCLYXTO/VENCLEXTA (venetoclax)-based combination therapy showed sustained long-term safety and efficacy.
|
|
2.
|
Merck & Co., Inc.
|
Merck & Co., Inc. is a leading global pharmaceutical company engaged in the research, development, manufacturing, and distribution of innovative medicines and vaccines. The company has a strong presence in immunology, oncology, infectious diseases, and other therapeutic areas. Merck focuses on biologic and small-molecule therapies targeting immune-mediated conditions.
|
|
North America, South America, Middle East and Africa, Asia-Pacific, and Europe
|
In January 2023, Merck & Co., Inc. announced the FDA had approved KEYTRUDA, Merck's anti-PD-1 therapy, as a single agent for adjuvant therapy following surgical resection and platinum-based chemotherapy for adult patients with stage IB (T2a 4 centimeters [cm]), II, or IIIA non-small cell lung cancer (NSCLC)
|
|
3.
|
Sanofi
|
Sanofi investigated rilzabrutinib, an oral Bruton’s tyrosine kinase (BTK) inhibitor, for the treatment of PV. The Phase 3 PEGASUS study aimed to evaluate its efficacy; however, the trial did not meet its primary or key secondary endpoints. Despite these results, Sanofi continues to explore rilzabrutinib's potential in other immune-mediated diseases.
|
|
North America, South America, Middle East and Africa, Asia-Pacific, and Europe
|
In March 2023, Sanofi announced that Dupixent (dupilumab) had been authorized by the European Commission (EC) for use in the European Union (EU) to treat severe atopic dermatitis in children who are candidates for systemic therapy and are aged 6 months to 5 years old. Dupixent is now the first and only targeted medication approved for treating these young children in Europe and the U.S.
|
|
4.
|
Regeneron Pharmaceuticals Inc.
|
Regeneron, in collaboration with Sanofi, developed Dupixent (dupilumab), a monoclonal antibody targeting the IL-4 receptor alpha subunit. While Dupixent has shown efficacy in treating atopic dermatitis and asthma, there is no current evidence supporting its use in pemphigus vulgaris.
|
|
North America, Asia-Pacific, and Europe
|
In September 2022, Regeneron Pharmaceuticals Inc. and Sanofi announced the U.S. Food and Drug Administration (FDA) had authorized Dupixent (dupilumab) for the treatment of adult patients with prurigo nodularis.
|
|
5.
|
Novartis AG
|
Novartis has been involved in developing therapies targeting autoimmune conditions. However, specific information regarding Novartis's products for the treatment of pemphigus vulgaris is not available based on the provided sources.
|
|
North America, South America, Middle East and Africa, Asia-Pacific, and Europe
|
In May 2023, Novartis AG announced the clinical trial study titled "Evaluating the Safety of Myfortic (Mycophenolate Sodium) in Patients With Lupus Nephritis: a 12 Month, Single-arm, and Observational Study in Taiwan Population"
|
Conclusion
The global pemphigus vulgaris market is poised for sustained expansion, driven by advancements in targeted therapies and increasing investments in rare disease research. While affordability and accessibility remain key challenges, ongoing drug development and regulatory support for orphan drugs are expected to enhance treatment availability. As awareness and diagnostic capabilities continue to improve, the market is expected to witness steady growth, with biologics playing a crucial role in shaping future treatment landscapes.
